NeuroOne updates ATM offering to $6.75M
NeuroOne Medical Technologies Corporation is updating its at-the-market equity program to register up to $6,750,000 of common stock for potential future sales through JonesTrading Institutional Services LLC as sales agent.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
NeuroOne Medical Technologies Corporation is updating its at-the-market equity program to register up to $6,750,000 of common stock for potential future sales through JonesTrading Institutional Services LLC as sales agent. This supplements earlier prospectus supplements under the same Capital on Demand Sales Agreement. The company has already sold approximately $8,000,600 under the agreement using the prior prospectus. The filing notes a non-affiliate market value of about $49.75 million for its common stock, based on 48,301,009 shares held by non-affiliates at $1.03 per share as of July 22, 2025, while the last reported Nasdaq price was $0.83 per share on August 14, 2025.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What is NeuroOne (NMTC) registering in this 424B5 supplement?
How does this new $6.75 million ATM amount relate to NeuroOne's prior authorization?
How much has NeuroOne already sold under the Sales Agreement?
What is the recent market value of NeuroOne (NMTC) common stock held by non-affiliates?
On which exchange is NeuroOne common stock listed and what was the latest price cited?
What SEC form framework does NeuroOne rely on for this offering capacity?
AI-generated analysis. How Rhea-AI works. Not financial advice.
Filed pursuant to Rule 424(b)(5)
Registration No. 333-279871
Prospectus Supplement
(To the Prospectus Supplements dated April 3, 2025 and August 16, 2024)
(To the Prospectus dated August 16, 2024)
NeuroOne Medical Technologies Corporation
$6,750,000
Common Stock
This prospectus supplement supplements the prospectus supplements dated August 16, 2024 and April 3, 2025 (the “Prior ATM Prospectus Supplement”), to the prospectus dated August 16, 2024 (the “Base Prospectus” and, together with the Prior ATM Prospectus Supplement, the “Prior Prospectus”), relating to the offer and sale of shares of our common stock, par value $0.001 per share, having an aggregate offering price of up to $4.7 million from time to time through JonesTrading Institutional Services LLC (“Jones”), as sales agent, in “at the market offerings” (as defined in Rule 415 promulgated under the Securities Act of 1933, as amended) pursuant to a Capital on Demand™ Sales Agreement (the “Sales Agreement”), dated December 21, 2022, that we entered into with Jones. As of the date hereof, we have sold an aggregate of approximately $8,000,600 pursuant to the Sales Agreement under the Prior Prospectus. We are filing this prospectus supplement to supplement the Prior Prospectus to increase the amount of shares registered that we are eligible to sell pursuant to the Sales Agreement to $6,750,000.
This prospectus supplement should be read in conjunction with the Prior Prospectus, and is qualified by reference to the Prior Prospectus in all respects, except to the extent that the information presented herein supersedes the information contained in the Prior Prospectus. This prospectus supplement is not complete without, and may only be delivered or used in connection with, the Prior Prospectus, including any amendments or supplements thereto.
Our common stock is listed on The Nasdaq Capital Market, or Nasdaq, under the symbol “NMTC.” On August 14, 2025, the last reported sale price of our common stock on Nasdaq was $0.83 per share.
The aggregate market value of our outstanding common stock held by non-affiliates pursuant to General Instruction I.B.6 of Form S-3 was approximately $49.75 million, which was calculated based on 48,301,009 shares of our outstanding common stock held by non-affiliates and a price of $1.03 per share, which was the price at which our common stock was last sold on the Nasdaq Capital Market on July 22, 2025. During the 12 calendar months prior to and including the date of this prospectus supplement, we have sold $9,614,037 of securities pursuant to General Instruction I.B.6 of Form S-3.
Investing in our securities involves a high degree of risk. See “Risk Factors” in the Original Prospectus and documents incorporated therein by reference for a discussion of such risk factors, which factors should be read carefully in connection with an investment in our securities.
Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the accuracy or adequacy of this prospectus supplement or the accompanying prospectus. Any representation to the contrary is a criminal offense.
Prospectus supplement dated August 15, 2025